Last Updated : October 6, 2022
Details
FilesGeneric Name:
selpercatinib
Project Status:
Complete
Therapeutic Area:
Thyroid cancer
Manufacturer:
Eli Lilly Canada Inc
Brand Name:
Retevmo
Project Line:
Reimbursement Review
Project Number:
PC0274-000
Tumour Type:
Head and Neck
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
Non
Manufacturer Requested Reimbursement Criteria1:
Retevmo is indicated as monotherapy for the treatment of:
RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Retevmo is indicated as monotherapy for the treatment of:
• RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones | |
|---|---|
| Call for patient/clinician input open | 14-Sep-21 |
| Call for patient/clinician input closed | 19-Nov-21 |
| Clarification: - Patient input submission received from GroupCanCertainty, Canadian Cancer Society’s patient panels and networks, and Thyroid Cancer Canada patient networks | |
| Submission received | 29-Oct-21 |
| Submission accepted | 09-Dec-21 |
| Review initiated | 10-Dec-21 |
| Draft CADTH review report(s) provided to sponsor for comment | 07-Mar-22 |
| Deadline for sponsors comments | 16-Mar-22 |
| CADTH review report(s) and responses to comments provided to sponsor | 29-Apr-22 |
| Expert committee meeting (initial) | 11-May-22 |
| Draft recommendation issued to sponsor | 25-May-22 |
| Draft recommendation posted for stakeholder feedback | 02-Jun-22 |
| End of feedback period | 16-Jun-22 |
| Final recommendation issued to sponsor and drug plans | 29-Jun-22 |
| Final recommendation posted | 18-Jul-22 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 14-Jul-22 |
| CADTH review report(s) posted | 05-Oct-22 |
Files
Last Updated : October 6, 2022